These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30953957)

  • 1. Intravenous use of valproic acid in status epilepticus is associated with high risk of hyperammonemia.
    Lind J; Nordlund P
    Seizure; 2019 Jul; 69():20-24. PubMed ID: 30953957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of valproate-induced hyperammonemia on treatment decision in an adult status epilepticus cohort.
    Habhab SF; Ulvin LB; Taubøll E; Svalheim S; Olsen KB; Horn MA; Heuser K
    Epilepsy Behav; 2020 Oct; 111():107193. PubMed ID: 32759060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
    Yamada H; Shishido T; Mukai T; Araki M; Naka H; Tokinobu H
    Rinsho Shinkeigaku; 2019 May; 59(5):258-263. PubMed ID: 31061301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperammonemia in Patients With Status Epilepticus Treated With or Without Valproic Acid.
    Smith KM; Britton JW; Hocker SE; Toledano M
    Neurologist; 2021 May; 26(3):80-82. PubMed ID: 33942787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of rapid IV administration of valproic acid for status epilepticus.
    Rossetti AO; Bromfield EB
    Neurology; 2005 Aug; 65(3):500-1; author reply 500-1. PubMed ID: 16087935
    [No Abstract]   [Full Text] [Related]  

  • 6. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial.
    Malamiri RA; Ghaempanah M; Khosroshahi N; Nikkhah A; Bavarian B; Ashrafi MR
    Eur J Paediatr Neurol; 2012 Sep; 16(5):536-41. PubMed ID: 22326977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-Carnitine supplementation to reverse hyperammonemia in a patient undergoing chronic valproic acid treatment: A case report.
    Maldonado C; Guevara N; Silveira A; Fagiolino P; Vázquez M
    J Int Med Res; 2017 Jun; 45(3):1268-1272. PubMed ID: 28425821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).
    Larsen EP; Ostergaard JR
    Seizure; 2014 Jun; 23(6):429-34. PubMed ID: 24647346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperammonemia secondary to the use of valproic acid: case report].
    Turcato Mde F; Fernandes RM; Wichert-Ana L; Funayama CA
    Arq Neuropsiquiatr; 2005 Jun; 63(2A):364-6. PubMed ID: 16100994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Valproate-associated hyperammonemic encephalopathy. Report of one case].
    Young P; Finn BC; Alvarez F; Bruetman JE; Trimarchi H
    Rev Med Chil; 2007 Nov; 135(11):1446-9. PubMed ID: 18259656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review.
    Trinka E; Höfler J; Zerbs A; Brigo F
    CNS Drugs; 2014 Jul; 28(7):623-39. PubMed ID: 24806973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carnitine supplementation for valproate-related hyperammonemia to maintain therapeutic valproate level.
    Sonik P; Hilty DM; Rossaro L; Bourgeois JA
    J Clin Psychopharmacol; 2011 Oct; 31(5):680-2. PubMed ID: 21881462
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyperammonemia and coma without hepatic dysfunction induced by valproate therapy.
    Barrueto F; Hack JB
    Acad Emerg Med; 2001 Oct; 8(10):999-1001. PubMed ID: 11581089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous sodium valproate in status epilepticus.
    Jha S; Jose M; Patel R
    Neurol India; 2003 Sep; 51(3):421-2. PubMed ID: 14652464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valproate-induced hyperammonemic encephalopathy: a case report and brief review of the literature.
    Sunkavalli KK; Iqbal FM; Singh B; Koneru J
    Am J Ther; 2013; 20(5):569-71. PubMed ID: 21248614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
    Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.
    Yamamoto Y; Takahashi Y; Suzuki E; Mishima N; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsy Res; 2012 Sep; 101(3):202-9. PubMed ID: 22542569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
    Mink S; Muroi C; Seule M; Bjeljac M; Keller E
    Clin Neurol Neurosurg; 2011 Oct; 113(8):644-8. PubMed ID: 21703756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sudden valproate-induced hyperammonemia managed with L-carnitine in a medically healthy bipolar patient: Essential review of the literature and case report.
    Cattaneo CI; Ressico F; Valsesia R; D'Innella P; Ballabio M; Fornaro M
    Medicine (Baltimore); 2017 Sep; 96(39):e8117. PubMed ID: 28953637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.